Abbisko Cayman Says US FDA Grants Rare Pediatric Disease Designation For FGFR2/3 Inhibitor ABSK061
ReutersMar 11, 2026 12:49 AM
March 11 (Reuters) - Abbisko Cayman Ltd 2256.HK:
US FDA GRANTS RARE PEDIATRIC DISEASE DESIGNATION FOR FGFR2/3 INHIBITOR ABSK061
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Index Fast-Track Nears Launch: Is Nasdaq’s Proposed Rule a “Tailor-Made Carve-Out” for SpaceX’s $175M IPO?
TradingKey - According to Reuters, as global capital market focus on the listings of tech giants continues to intensify, SpaceX’s potential initial public offering (IPO) is becoming one of the most closely watched deals on Wall Street.TradingKey
15 hours ago
CRCL Beyond $100: Decoding the Forces Behind Circle’s 100% Rally and the Quest for $300
Circle leads crypto stocks, surging 107% over the past month to $110 and entering a critical zone.TradingKey
20 hours ago
Micron vs. Samsung vs. SK Hynix: Is MU Stock the Best Memory Stock for 2026?
TradingKey - Relying on strong AI demand, more memory per system, and sluggish supply response, 2026 will be the memory cycle. Micron Technology (MU) is now in an excellent competitive position today with HBM3E and looking to ramp HBM4E into Nvidia’s Vera Rubin platforms in the second half of 2026.TradingKey
20 hours ago
